CDK12突变在前列腺癌发生和发展以及临床诊疗中的研究进展

Progress in CDK12 mutation in occurrence and development of prostate cancer and its clinical diagnosis and treatment

前列腺癌的分子生物学和基因层面的高度异质性,导致了不同的治疗反应和临床结局。随着基因组学和测序技术的发展,人们对前列腺癌的基因组特征有了更加深入的理解。CDK12突变被报道与前列腺癌的不良临床结局密切相关,并且可能成为不同治疗方案的潜在疗效预测标志物。本文对前列腺癌中CDK12突变的数据和研究现况进行总结,讨论了携带CDK12突变的前列腺癌的分子和临床特征以及对不同治疗方案的反应,阐述了CDK12突变在前列腺癌发生和发展以及临床诊疗中的意义。

The high heterogeneity of molecular biology and gene level of prostate cancer leads to different treatment reactions and clinical outcomes.With the development of genomics and sequencing technology,people have a deeper understanding of the genomic characteristics of prostate cancer.CDK12 mutation has been reported to be closely related to the adverse clinical outcome of prostate cancer,and may become a potential therapeutic marker for different treatment schemes.This review summarizes the data and research status of CDK12 mutation in prostate cancer,discusses the molecular and clinical characteristics of prostate cancer carrying CDK12 mutation and the response to different treatment schemes,and expounds the significance of CDK12 mutation in the occurrence and development of prostate cancer and its clinical diagnosis and treatment.